<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150797</url>
  </required_header>
  <id_info>
    <org_study_id>16-19623</org_study_id>
    <nct_id>NCT03150797</nct_id>
  </id_info>
  <brief_title>Melatonin for Adolescent Migraine Prevention Study</brief_title>
  <acronym>MAP</acronym>
  <official_title>Melatonin for Adolescent Migraine Prevention Study (The MAP Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy Gelfand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, multi-site double-blind placebo-controlled trial of melatonin (2&#xD;
      different dosing arms) vs. placebo for migraine prevention in adolescents. We intend to&#xD;
      enroll approximately 210 participants over 15 months at two sites: UCLA and UCSF. The&#xD;
      duration of participation for each participant will be 4 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participation includes 16 weeks of daily headache diary recording and taking the study pill&#xD;
      every night, 1-2 hours before bed. Aside from the initial 1 hour enrollment visit, all&#xD;
      remaining study procedures will be completed from home.&#xD;
&#xD;
      During the enrollment visit, history of migraine, questionnaires, a neurologic and physical&#xD;
      exam (including weight, blood pressure, pulse, and respiratory rate) will be performed. Girls&#xD;
      who have had their first period will undergo a urine pregnancy test and will be instructed to&#xD;
      use birth control if they are sexually active.&#xD;
&#xD;
      For the first 8 week phase, participants will be instructed to take one study pill every&#xD;
      night, 1-2 hours before bedtime and complete a daily headache diary from a smartphone. Phone&#xD;
      call check-ins will occur at week 4 and week 8.&#xD;
&#xD;
      After the first 8 weeks of the study, participants who are eligible for the second phase of&#xD;
      the study will be notified by study staff and will be sent the next set of study pills.&#xD;
      Again, participants will be instructed to take the study pill every night, 1-2 hours before&#xD;
      bedtime and complete a diary entry every evening.&#xD;
&#xD;
      Phone call check-ins will occur at week 12 and week 16. At the final 16 week phone call,&#xD;
      additional questionnaires and study completion feedback will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient Fund&#xD;
  </why_stopped>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo.</measure>
    <time_frame>weeks 5-8 of randomized treatment phase</time_frame>
    <description>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group.</measure>
    <time_frame>Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PedMIDAS (headache related disability score) in weeks 5-8 of randomized treatment phase in each melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Mean PedMIDAS (headache related disability score) in weeks 5-8 of randomized treatment phase in each melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</measure>
    <time_frame>Weeks 5-8 of randomized treatment phase.</time_frame>
    <description>Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Melatonin 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 3mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 6mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin</description>
    <arm_group_label>Melatonin 3mg</arm_group_label>
    <arm_group_label>Melatonin 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo oral capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 10-17-inclusive&#xD;
&#xD;
          2. Weight â‰¥40 kg, so as not to require mg/kg based dosing&#xD;
&#xD;
          3. Meets International Classification of Headache Disorders III beta1 criteria for&#xD;
             migraine in children/adolescents (international standard diagnostic criteria for&#xD;
             research)&#xD;
&#xD;
          4. Lives in the state of California- to allow shipping of study medication from our&#xD;
             pharmacy&#xD;
&#xD;
          5. Has at least one parent who speaks English-in order to ensure good communication with&#xD;
             study team by phone&#xD;
&#xD;
          6. Has daily access to a smartphone in order to provide daily headache diary data&#xD;
&#xD;
          7. A Parent/Guardian consents and the adolescent is cognitively capable of giving assent&#xD;
             to participate&#xD;
&#xD;
          8. Either not on a migraine preventive medication, or if on one the dose has been stable&#xD;
             for at least 4 weeks prior to enrollment, or are willing to wait to start the study&#xD;
             until they have reached a stable dose for 4 weeks&#xD;
&#xD;
          9. Willing to not use OTC melatonin or change migraine preventives during the trial&#xD;
&#xD;
         10. Has â‰¥1 headache day per week, or 4-28 days of headache in a 28-day period Episodic&#xD;
             headaches have been present for a minimum of 6 months-This lowers the likelihood of a&#xD;
             secondary cause of headaches&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Continuous headache&#xD;
&#xD;
          2. History of seizures/epilepsy&#xD;
&#xD;
          3. Pregnant/lactating&#xD;
&#xD;
          4. Concomitant opioid or barbiturate overuse, wherein overuse is defined as â‰¥4 days per&#xD;
             month of barbiturate containing compounds, â‰¥10 days per month of opioid containing&#xD;
             compounds as these may impact sleepiness scales&#xD;
&#xD;
          5. If in the investigator's opinion there is a medical or psychiatric concern that makes&#xD;
             them think the participant should not participate&#xD;
&#xD;
          6. Inability to swallow pills after teaching and practice History of nocturnal asthma, as&#xD;
             evidenced by a having a diagnosis of asthma and symptoms that manifest as nighttime&#xD;
             awakening due to cough, wheeze, and/or shortness of breath&#xD;
&#xD;
        Randomization Criteria:&#xD;
&#xD;
          1. Had 4-28 migraine/migrainous days in the 28-day period of weeks 5-8 of single-blind&#xD;
             placebo treatment phase, but not continuous headache.&#xD;
&#xD;
          2. At least 80% compliance with headache diary (i.e. at least 23 headache diary days)&#xD;
             during weeks 5-8 of single-blind placebo treatment phase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy A Gelfand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Headache Research and Treatment Program</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco, (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658.</citation>
    <PMID>23771276</PMID>
  </reference>
  <reference>
    <citation>Bigal ME, Lipton RB, Winner P, Reed ML, Diamond S, Stewart WF; AMPP advisory group. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007 Jul 3;69(1):16-25.</citation>
    <PMID>17606878</PMID>
  </reference>
  <reference>
    <citation>Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012 Oct 30;79(18):1881-8. doi: 10.1212/WNL.0b013e318271f812.</citation>
    <PMID>23109652</PMID>
  </reference>
  <reference>
    <citation>Chang YS, Lin MH, Lee JH, Lee PL, Dai YS, Chu KH, Sun C, Lin YT, Wang LC, Yu HH, Yang YH, Chen CA, Wan KS, Chiang BL. Melatonin Supplementation for Children With Atopic Dermatitis and Sleep Disturbance: A Randomized Clinical Trial. JAMA Pediatr. 2016 Jan;170(1):35-42. doi: 10.1001/jamapediatrics.2015.3092.</citation>
    <PMID>26569624</PMID>
  </reference>
  <reference>
    <citation>GonÃ§alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1127-32. doi: 10.1136/jnnp-2016-313458. Epub 2016 May 10.</citation>
    <PMID>27165014</PMID>
  </reference>
  <reference>
    <citation>Masruha MR, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008 Aug;9(4):221-4. doi: 10.1007/s10194-008-0047-5. Epub 2008 Jul 2.</citation>
    <PMID>18594760</PMID>
  </reference>
  <reference>
    <citation>Masruha MR, Lin J, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF. Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache. 2010 Mar;50(3):413-9. doi: 10.1111/j.1526-4610.2009.01547.x. Epub 2009 Oct 8.</citation>
    <PMID>19817880</PMID>
  </reference>
  <reference>
    <citation>Alstadhaug KB, Odeh F, Salvesen R, Bekkelund SI. Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology. 2010 Oct 26;75(17):1527-32. doi: 10.1212/WNL.0b013e3181f9618c.</citation>
    <PMID>20975054</PMID>
  </reference>
  <reference>
    <citation>Bougea A, Spantideas N, Lyras V, Avramidis T, Thomaidis T. Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study. Funct Neurol. 2016 Jan-Mar;31(1):33-7.</citation>
    <PMID>27027892</PMID>
  </reference>
  <reference>
    <citation>Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015;10(2):132-5.</citation>
    <PMID>24909684</PMID>
  </reference>
  <reference>
    <citation>Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP. Melatonin to prevent migraine or tension-type headache in children. Neurol Sci. 2008 Sep;29(4):285-7. doi: 10.1007/s10072-008-0983-5. Epub 2008 Sep 20.</citation>
    <PMID>18810607</PMID>
  </reference>
  <reference>
    <citation>Spilsbury JC, Drotar D, Rosen CL, Redline S. The Cleveland adolescent sleepiness questionnaire: a new measure to assess excessive daytime sleepiness in adolescents. J Clin Sleep Med. 2007 Oct 15;3(6):603-12.</citation>
    <PMID>17993042</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <disposition_first_submitted>January 27, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 29, 2021</disposition_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Amy Gelfand</investigator_full_name>
    <investigator_title>Director of Pediatric Headache UCSF Benioff Children's Hospital</investigator_title>
  </responsible_party>
  <keyword>UCSF</keyword>
  <keyword>UCLA</keyword>
  <keyword>melatonin</keyword>
  <keyword>migraine</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

